Ifosfamide
- Generic Name
- Ifosfamide
- Brand Names
- Ifex
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 3778-73-2
- Unique Ingredient Identifier
- UM20QQM95Y
- Background
Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.
- Indication
Used as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indications include treatment of osteosarcoma, bladder cancer, ovarian cancer. small cell lung cancer, and non-Hodgkin's lymphoma.
- Associated Conditions
- Bladder Cancer, Cervical Cancer, Ewing's Sarcoma, Head And Neck Cancer, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma (NHL), Osteosarcoma, Ovarian Cancer, Pancreatic Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Testicular Germ Cell Cancer, Thymoma
- Associated Therapies
- -
Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors
- First Posted Date
- 2007-02-07
- Last Posted Date
- 2022-05-17
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 23
- Registration Number
- NCT00432094
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: asparaginaseDrug: cyclophosphamideDrug: cytarabineDrug: daunorubicin hydrochlorideDrug: dexamethasoneDrug: doxorubicin hydrochlorideDrug: ifosfamideDrug: etoposideDrug: mercaptopurineDrug: methotrexateDrug: prednisoneDrug: thioguanineDrug: vincristine sulfateDrug: vindesineRadiation: radiation therapy
- First Posted Date
- 2007-02-01
- Last Posted Date
- 2013-05-29
- Lead Sponsor
- University Hospital Schleswig-Holstein
- Target Recruit Count
- 4559
- Registration Number
- NCT00430118
- Locations
- 🇦🇹
LKH Leoben, Leoben, Austria
🇦🇹Landeskrankenhaus Feldkirch, Feldkirch-Tisis, Austria
🇦🇹Universitaet Kinderklinik, Graz, Austria
Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin
- Conditions
- Interventions
- First Posted Date
- 2007-01-18
- Last Posted Date
- 2016-05-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 26
- Registration Number
- NCT00423852
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma
- Conditions
- First Posted Date
- 2006-12-13
- Last Posted Date
- 2013-08-07
- Target Recruit Count
- 642
- Registration Number
- NCT00410631
- Locations
- 🇩🇪
Kinderklinik - Universitaetsklinikum Aachen, Aachen, Germany
🇩🇪Klinikum Dortmund, Dortmund, Germany
🇩🇪Kliniken der Stadt Koeln gGmbH - Kinderkrankenhaus Riehl, Cologne, Germany
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2006-10-26
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- AIDS Malignancy Consortium
- Target Recruit Count
- 34
- Registration Number
- NCT00392834
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸UCLA Clinical AIDS Research and Education (CARE) Center, Los Angeles, California, United States
🇺🇸Floyd and Delores Jones Cancer Institute at Virginia Mason Medical Center, Seattle, Washington, United States
Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy
- Conditions
- Stage III Childhood Hodgkin LymphomaStage IV Childhood Hodgkin LymphomaAdult Lymphocyte Predominant Hodgkin LymphomaChildhood Mixed Cellularity Hodgkin LymphomaChildhood Nodular Lymphocyte Predominant Hodgkin LymphomaRecurrent/Refractory Childhood Hodgkin LymphomaStage I Adult Hodgkin LymphomaStage I Childhood Hodgkin LymphomaAdult Lymphocyte Depletion Hodgkin LymphomaChildhood Nodular Sclerosis Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2006-09-28
- Last Posted Date
- 2021-03-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 26
- Registration Number
- NCT00381940
- Locations
- 🇺🇸
Children's Oncology Group, Philadelphia, Pennsylvania, United States
Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma
- Conditions
- First Posted Date
- 2006-09-21
- Last Posted Date
- 2013-08-12
- Target Recruit Count
- 600
- Registration Number
- NCT00379457
- Locations
- 🇸🇪
Uppsala University Hospital, Uppsala, Sweden
🇩🇰Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark
🇮🇪Our Lady's Hospital for Sick Children Crumlin, Dublin, Ireland
Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2018-03-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 5
- Registration Number
- NCT00354107
- Locations
- 🇺🇸
Children's Oncology Group, Philadelphia, Pennsylvania, United States
High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2020-01-29
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 109
- Registration Number
- NCT00354744
- Locations
- 🇺🇸
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸Nemours Children's Clinic, Jacksonville, Florida, United States
🇺🇸Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center, Farmington, Connecticut, United States
Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
- Conditions
- Adult Extraskeletal OsteosarcomaAdult Malignant Fibrous HistiocytomaChildhood FibrosarcomaChildhood LiposarcomaMetastatic Childhood Soft Tissue SarcomaNonmetastatic Childhood Soft Tissue SarcomaStage I Adult Soft Tissue SarcomaStage III Adult Soft Tissue SarcomaAdult AngiosarcomaAdult Epithelioid Sarcoma
- Interventions
- First Posted Date
- 2006-06-29
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 588
- Registration Number
- NCT00346164
- Locations
- 🇺🇸
Driscoll Children's Hospital, Corpus Christi, Texas, United States
🇺🇸New York Medical College, Valhalla, New York, United States
🇺🇸Children's Hospital Central California, Madera, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.